How much weight loss did the new oral GLP-1 pill produce in 36 weeks?

News summary

ScienceDaily reported that the experimental oral drug aleniglipron, a small-molecule GLP-1 receptor agonist, produced substantial weight loss over 36 weeks. The Nature Medicine paper supports the core story: 230 participants were randomized to different doses or placebo, with greater weight reduction at higher doses. The news headline's 'up to 12%' refers to the raw change at the highest dose, while the primary placebo-adjusted analysis showed a maximum reduction of about 11.3%.

At week 36, placebo-adjusted weight reductions were about 8.2%, 9.8%, and 11.3% for the 45, 90, and 120 mg doses, respectively. Gastrointestinal events were the most common adverse effects and were generally mild to moderate; treatment-related discontinuations occurred in 10.4% of aleniglipron-treated participants.

The findings suggest that an oral small-molecule GLP-1 drug could become a useful obesity treatment, but aleniglipron remains experimental. A positive phase 2b result does not mean it is ready for routine use; longer-term efficacy and safety still need confirmation in phase 3 trials.

The double-blind phase lasted 36 weeks and was not designed to assess long-term outcomes such as cardiovascular events. The drug developer was involved in the study. A publisher correction was issued in June 2026; this AliLab summary is based on the updated article.